iShares Genomics Immunology and Healthcare ETF
$40.79−0.77 (−1.85%)
- 0.47%
- $315M
- +74.8%
- 0.68%
- 0.1M sh
- $41.46
- low $23.90high $43.44
The ETF.net IDNA Grade
B
Score 56 out of 100
- 7 of 17
Score 56 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.B56 out of 100Rank 7 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.B67 out of 100Rank 6 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.C53 out of 100Rank 8 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.C46 out of 100Rank 13 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.B62 out of 100Rank 7 of 17
Our read on IDNA
BMost biotech ETFs hand you the US biotech index. IDNA goes narrower and wider at once: about 50 companies from developed and emerging markets, picked around genomics, immunology and bioengineering.
The Fund seeks to track an index of developed- and emerging-market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering.
Why people hold it
- The mandate is specific: an index of developed- and emerging-market companies tied to genomics, immunology and bioengineering, not a catch-all biotech basket.ishares.com
- 0.47% a year, a shade under the typical fund in its genomics-and-biotech peer group.
- About 50 holdings, so individual genomics and immunology names carry real weight instead of getting diluted inside a broad healthcare index.
- Running since 2019 under the iShares roof, and it stands in the upper half of its biotech and genomics peer group.
Worth knowing
- Concentration cuts both ways: about 50 stocks in one theme, so single-company clinical news lands harder here than in a broad healthcare fund.
- Smaller and less actively traded than the category's giants, so limit orders earn their keep. Emerging-market holdings add currency and local-market risk.
- Broad biotech index funds charge less, IBBQ at 0.19% and IBB at 0.44%; the extra basis points here buy the global genomics-and-immunology tilt.
IDNA Holdings
- Stocks
- 62
- 49%
- MRNA
Sectors
- Health Care100.0%
Geography
- United States66.28%
- Germany6.50%
- France5.56%
- Japan4.89%
- Switzerland4.38%
- Denmark4.27%
- Canada2.73%
- United Kingdom2.63%
- 2.77%
Developed 94% · Emerging 6%
IDNA Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.
IDNA$17,478
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IDNA |
|---|---|
| Year to date | +59.4% |
| 1 month | +9.2% |
| 3 months | +23.9% |
| 1 year | +74.8% |
| 3 years | +30.8% |
| 5 years | −1.9% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IDNA |
|---|---|---|
| 2026 YTD | +59.4% | |
| 2025 | +17.3% | |
| 2024 | −0.7% | |
| 2023 | −7.6% | |
| 2022 | −42.3% | |
| 2021 | −4.0% | |
| 2020 | +54.3% |
IDNA in the news
IDNA Dividends
- 0.68%
- $0.28
- $0.13 per share
- Twice a year
Distribution history
IDNA Risk
- 24.8%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.97
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −65.7%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.11
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IDNA Cost
0.47%
IDNA0.47%
- The middle half of Biotech & Genomics funds
- Median 0.47%
7 of the 17 Biotech & Genomics funds charge less.
Other funds in Biotech & Genomics
- BBBHVanEck Biotech ETFExpense ratio 0.35%1 year return +39.7%
- BFBTFirst Trust NYSE Arca Biotechnology Index FundExpense ratio 0.55%1 year return +44.7%
- BPBEInvesco Biotechnology & Genome ETFExpense ratio 0.59%1 year return +39.2%
- CSBIOALPS Medical Breakthroughs ETFExpense ratio 0.50%1 year return +31.0%
- CIBRNiShares Neuroscience and Healthcare ETFExpense ratio 0.47%1 year return +15.3%